1. Home
  2. XXII vs DCOY Comparison

XXII vs DCOY Comparison

Compare XXII & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 22nd Century Group Inc.

XXII

22nd Century Group Inc.

HOLD

Current Price

$0.56

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$5.70

Market Cap

3.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XXII
DCOY
Founded
1998
N/A
Country
United States
United States
Employees
N/A
11
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.1M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
XXII
DCOY
Price
$0.56
$5.70
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$30.00
AVG Volume (30 Days)
1.0M
7.5K
Earning Date
05-12-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
69.96
N/A
EPS
N/A
N/A
Revenue
$25,832,530.00
N/A
Revenue This Year
$370.28
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.53
52 Week High
$11.37
$9.09

Technical Indicators

Market Signals
Indicator
XXII
DCOY
Relative Strength Index (RSI) 16.90 48.96
Support Level N/A $5.28
Resistance Level $1.10 $6.70
Average True Range (ATR) 0.21 0.38
MACD -0.05 -0.02
Stochastic Oscillator 2.44 50.46

Price Performance

Historical Comparison
XXII
DCOY

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Share on Social Networks: